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The combination of doxorubicin and cyclophosphamide commonly used to treat breast cancer can cause premature ovarian failure
and infertility. 𝛼-Tocopherol is a potent antioxidant whereas 𝛾-tocopherol causes apoptosis in a variety of cancer models in vitro
including breast cancer.We hypothesised that the combination of doxorubicin (Dox) and 4-hydroperoxycyclophosphamide (4-Cyc)
would be more cytotoxic in vitro than each agent alone, and that 𝛼-tocopherol would reduce and 𝛾-tocopherol would augment the
cytotoxicity of the combined chemotherapeutics.HumanMCF-7 breast cancer and KGN ovarian cells were exposed to Dox, 4-Cyc,
combinedDox and 4-Cyc, 𝛼-tocopherol, 𝛾-tocopherol, or a combination of Dox and 4-Cyc with 𝛼-tocopherol or 𝛾–tocopherol. Cell
viability was assessed using a crystal violet assay according to four schedules: 24h exposure, 24h exposure + 24h culture inmedium,
24h exposure + 48h culture in medium, or 72h continuous exposure. Supernatants from each separate KGN culture experiment
(n=3) were examined using an estradiol ELISA. Dox was cytotoxic to both MCF-7 and KGN cells, but 4-Cyc only killed MCF-7
cells. 𝛾-Tocopherol significantly decreased MCF-7 but not KGN cell viability. The combined chemotherapeutics and 𝛾-tocopherol
were more cytotoxic to MCF-7 than KGN cells, and 𝛼-tocopherol reduced the cytotoxicity of the combined chemotherapeutics
towards KGN ovarian cells, but not MCF-7 cells. The addition of both 𝛾-tocopherol and 𝛼-tocopherol to the chemotherapeutic
combination of Dox and cyclophosphamide has the potential to increase in vitro chemotherapeutic efficacy against breast cancer
cells whilst decreasing cytotoxicity towards ovarian granulosa cells.
1. Introduction
In Asia, approximately 25% of all breast cancer patients are
premenopausal and younger than 35 years old [1].Worldwide,
up to 90% of breast cancer patients can survive for 5 years fol-
lowing diagnosis [2, 3] but it was found that chemotherapy-
induced premature ovarian failure and infertility reduce the
survivors quality of life [4–10].
Many types of breast cancer are treated with a com-
bination of chemotherapeutic agents such as doxorubicin
(adriamycin) and cyclophosphamide [3, 11, 12]. Clinical
administration [13, 14] resulted in plasma concentrations
of 1.8±0.4𝜇M doxorubicin within 24h of infusion [15] and
serum concentrations of 4-hydroxycyclophosphamide to be
approximately 0.02uM 2-4h after administration [16].
Cyclophosphamide, an alkylating agent, requires hep-
atic activation to form 4-hydroxycyclophosphamide and
aldophosphamide, which coexist in equilibrium and dif-
fuse freely into cells. Aldophosphamide is metabolised
into phosphoramide mustard [17, 18] which causes intra-
and interstrand crosslinking in DNA. This interferes with
DNA replication [19] and stimulates apoptosis [17]. A syn-
thetic compound, 4-hydroperoxycyclophosphamide (4-Cyc),
is metabolised to 4-hydroxycyclophosphamide in vitro [13,
20] and in vivo [21, 22]. Aldehyde dehydrogenase oxidises
aldophosphamide to an inactive metabolite instead of the
active phosphoramidemustard, and hence cells with different
levels of aldehyde dehydrogenase respond differently to 4-
Cyc [18].
Doxorubicin (Dox), an anthracycline agent, intercalates
at double strand DNA breaks in a topoisomerase-II depen-
dent manner and inhibits DNA replication, synthesis, and
mitosis [23, 24]. Dox also induces the production of reactive
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oxygen species (ROS) which cause lipid peroxidation and
apoptosis [25]. The combined administration of both drugs
caused therapeutic synergism in a mouse model [26] that
was attributed to these different mechanisms of action:
cyclophosphamide crosslinking of DNA strands and Dox
prevention of DNA repair [27].
The chemotherapeutic combination of Dox and
cyclophosphamide causes premature ovarian failure in
premenopausal breast cancer patients [10, 18, 28]. Ovaries
contain follicles, a spherical structure consisting of a single
oocyte (egg) surrounded by layers of dividing granulosa cells.
Granulosa cells produce anti-Mu¨llerian hormone (AMH)
which inhibits activation of small, quiescent primordial
follicles [29]. It is thought that chemotherapeutics cause
granulosa cell death [30, 31], which reduces AMH and results
in the activation of primordial follicles [10]. The granulosa
cells in the activated follicles proliferate and the follicles
grow, but subsequent cycles of Dox and cyclophosphamide
therapy cause granulosa cell death and loss of these follicles
[32, 33]. Hence chemotherapy to treat breast cancer reduces
serum concentrations of AMH, depletes the ovary of its
reservoir of quiescent primordial follicles, and advances
infertility through premature ovarian failure [10, 34]. The
administration of cyclophosphamide to rodents caused
a dose-dependent loss of small follicles [32, 35, 36] with
DNA double strand breaks in the oocytes [37]. Dox caused
apoptosis in mature murine oocytes [38, 39] and the in vivo
administration of Dox to mice significantly reduced the
numbers of follicles, whilst increasing ovarian apoptosis
[40, 41]. It is clear that cyclophosphamide alone, or Dox
alone, has adverse effects on the follicular granulosa cells of
the ovary, but there are no reports describing the cytotoxic
effects of the combined regime (which is used to treat breast
cancer patients) on ovarian granulosa cells.
Dox-induced ROS damage was significantly lower in
mice administered vitamin E [42, 43], and vitamin E
decreased the toxicity of Dox without reducing its effective-
ness as chemotherapeutic agent [44–49]. Vitamin E consists
of eight structurally distinct compounds classified as toco-
pherols (alpha, beta, gamma, and delta) and tocotrienols
(alpha, beta, gamma, and delta) [50–53]. Tocopherols have
antioxidant activity against ROS-induced lipid peroxidation
[54, 55], and gamma tocopherol (𝛾Toc) is the prominent form
in the human diet [56].
The administration of 𝛼-tocopherol (𝛼Toc) to 21 breast
cancer patients prior to chemotherapy significantly elevated
serum concentrations of 𝛼Toc but did not augment efficacy
of the chemotherapeutics and did not decrease toxic side-
effects, although ovarian function was not assessed in this
study [57]. It seems that long-term dietary supplementation
with antioxidant vitamins reduces the incidence, but not
the severity, of cancer [58, 59]. Klein et al. [60] reported
that 𝛼Toc did not have anticancer properties in vivo, but
when the human breast cancer MCF-7 cell line was used
to generate tumours in mice, the dietary administration of
either 𝛼Toc or 𝛾Toc reduced tumour growth [53]. Delta and
𝛾Toc increased the levels of proapoptotic proteins, inhibited
expression of antiapoptotic proteins in vivo, and also had
antitumour activity in animal models of colon and prostate
cancer [52]. 𝛾Toc inhibited the proliferation of human breast
cancer cells in vitro [52, 61], delayed the formation of breast
cancer tumours in rodentmodels [52], and induced apoptosis
in breast cancer cells via upregulation of DR5 expression
[60]. Estrogen metabolism can generate ROS and this may
contribute to the pathogenesis of breast cancer [53]. This
also suggests that antioxidant tocopherols may have more
anticancer activity in vivo than in estrogen-free in vitro
systems.
We hypothesised that the combination of Dox and
cyclophosphamide would be more cytotoxic in vitro to
the human MCF-7 breast cancer cell line and the human
ovarian granulosa tumour-derived KGN cell line than each
chemotherapeutic agent alone [26]. Both alpha and gamma
tocopherol are antioxidants with the potential to reduce
chemotherapeutic-induced ROS damage and consequently
reduce cytotoxicity, but 𝛾Toc additionally has anticancer
activity. We therefore hypothesised that 𝛾Toc, but not 𝛼Toc,
would augment the cytotoxic activity of the combined Dox
and cyclophosphamide regime in vitro.
2. Materials and Methods
2.1. Chemicals and Reagents. All chemicals and reagents used
in this study were obtained from Sigma-Aldrich (Australia),
unless specified otherwise.
2.2. Preparation of Solutions. Stock solutions of 100𝜇Mdoxo-
rubicin (Dox) and 1000𝜇M 4-hydroperoxycyclophosph-
amide (4-Cyc, ThermoFisher Scientific, Victoria, Australia)
were prepared in RPMI media and 10% foetal calf serum
(FCS, DKSH, Victoria, Australia) for MCF-7 cells or in
DMEM/F12 media and 10% FCS for KGN cells. These
solutions were kept at 4∘C and -20∘C, respectively, for a
maximum of 3 months and were diluted immediately before
use, because these conditions maintain activity and stability
[62, 63]. Stock solutions of alpha and gamma tocopherol
(𝛼Toc and 𝛾Toc) were prepared by diluting the compounds
in dimethyl sulfoxide (DMSO) to yield solutions of 1000𝜇M.
These were stored for a maximum of 3 months at 4∘C.
Further dilutions in the appropriate cell culturemediumwere
prepared immediately before use, and cells were exposed to
0.8% DMSO. The 0.5% crystal violet stain was prepared in
a 50% methanol (99.9% pure). 100% acetic acid was diluted
to 33% with demineralised water, to be used as a destaining
solution in the crystal violet assay.
2.3. Cell Culture. TheMCF-7 human epithelial breast adeno-
carcinoma cell line was obtained from the America Type Cul-
tureCollection (ATCC) andmaintained in RPMImedia, sup-
plemented with 10% FCS and 1% v/v of 10,000 units/mL peni-
cillin + 10mg/mL streptomycin. Media were replaced every
2-3 days and cells were harvested with 0.1% trypsin/EDTA
solution and subcultured twice a week. The KGN human
granulosa carcinoma cell line [64] was kindly donated by Dr.
Theresa Hickey, Research Centre for Reproductive Health,
Department of Obstetrics and Gynaecology, University of
Adelaide, and maintained in DMEM/F12 supplemented with
insulin (5𝜇g/mL), transferrin (5𝜇g/mL), selenium (5ng/mL,
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Table 1: Concentrations of chemotherapeutics and tocopherols. Dox: doxorubicin, 4-Cyc: 4-hydroperoxycyclophosphamide, 𝛼Toc: 𝛼-
tocopherol, 𝛾Toc: 𝛾-tocopherol.
(a)
Single agents Concentrations (𝜇M)
Dox 0.5, 10, 25
4-Cyc 0, 0.5, 1, 2.5
𝛼Toc 0, 50, 75, 100
𝛾Toc 0, 50, 75, 100
(b)
Combined agents Concentrations (𝜇M)
Dox + 4-Cyc Low 10 (Dox) + 1 (4-Cyc)
Dox + 4-Cyc High 25 (Dox) + 2.5 (4-Cyc)
Dox + 4-Cyc + 𝛼Toc Low 10 (Dox) + 1 (4-Cyc) + 75 (𝛼Toc)
Dox + 4-Cyc + 𝛼Toc High 25 (Dox) + 2.5 (4-Cyc) 75 (𝛼Toc)
Dox + 4-Cyc + 𝛾Toc Low 10 (Dox) + 1 (4-Cyc) + 75 (𝛾Toc)
Dox + 4-Cyc + 𝛾Toc High 25 (Dox) + 2.5 (4-Cyc)+ 75 (𝛾Toc)
ITS), 10% FCS, and 1% v/v of 10,000 units/mL penicillin
+ 10mg/mL streptomycin. Although the KGN cell line was
derived from an ovarian granulosa cell carcinoma, it can be
used as a model for human ovarian granulosa cell growth,
apoptosis, and steroid hormone production [64]. Media were
replaced every 2-3 days and both cell lines were subcultured
twice a week. Cell culture flasks containing 80% confluent
cells in exponential growth phase were used for all experi-
ments.
2.4. Effect of Doxorubicin, 4-Hydroperoxycyclophosphamide,
and 𝛼- and 𝛾-Tocopherol on MCF-7 and KGN Cell Viability.
MCF-7 cells (20,000 cells per well) and KGN cells (25,000
cells per well) were added to 96-well microplates. After a
24h adherence period, supernatants were removed and cells
were exposed to 100𝜇L of chemotherapeutics or tocopherols
(Table 1). The chemotherapeutic doses selected for this in
vitro study bracket the clinical, in vivo serum concentrations
of Dox [15] and 4-hydroxycyclophosphamide [16] (Table 1).
Cells were exposed to chemotherapeutics and tocopherols
according to four different schedules: 24h exposure, 24h
exposure + 24h culture in media, 24h exposure + 48h
culture in media, or 72h continuous exposure where reagents
in medium + 10% FCS were replenished every 24h. After
exposure to chemotherapeutics and tocopherols, media con-
taining reagents were collected and frozen, and the cell
viability was assessed by the crystal violet (CV) assay. Each
test condition was examined in three replicate wells and each
experiment was repeated on 3 separate occasions (n=3) for
the two cell types.
2.5. Crystal Violet (CV) Cell Viability Assay. Cell culture
supernatants were replaced with 50𝜇L of crystal violet stain
(0.5%). The cells were stained and fixed for 10min at room
temperature. Excess stain was rinsed away with deminer-
alised water, and cells were left to air-dry overnight. 50𝜇L
of destaining solution was added for 10min. The optical
density was read at 570nm with correction at 630nm [65].
A crystal violet standard plot was produced in each replicate
experiment in which MCF-7 cell densities ranged from 0 to
80,000 and KGN cell densities from 0 to 100,000 cells per well
in replicates of 6 for each cell density. Absorbance readings
were plotted against cell densities with an average linear cor-
relation of R2 = 0.99 (n=3) replicate experiments for MCF-7
cells and R2 = 0.97 (n=3) replicate experiments for KGN cells.
Numbers of viable cells after exposure to chemotherapeutics
and/or tocopherols were determined by comparison with the
CV standard curve for the same experimental replicate.
2.6. Estradiol Enzyme-Linked Immunosorbent Assay (ELISA).
Supernatants from each KGN culture experiment (n=3)
were examined in a competitive estradiol ELISA (Cayman
Chemical ELISA, Ann Arbor, MI, USA) that uses a mouse
anti-rabbit IgG and an acetylcholinesterase estradiol tracer.
Detection ranges from 6.6 to 4000 pg/mL, and the intra-
assay coefficient of variation (CoV) ranges from 7.8 to 18.8%.
For this study, the estradiol standard was diluted in the
DMEM/F12 cell culture medium to give concentrations that
ranged from 6.6 to 4000 pg/mL. A separate standard plot
was constructed for each experimental replicate (n=3) and
the lowest R2 value was 0.99. Concentration of estrogen was
determined by comparison with the standard curve. Estro-
gen/cell concentration was calculated by dividing pg/mL of
estrogen for each culture well by the numbers of viable cells
in the same well.
3. Statistical Analysis
To examine the dose-dependent effect of chemotherapeutics
and/or tocopherols, a one-way ANOVA with Tukey HSD
and Bonferroni post hoc was conducted. To examine the
effect of the four different exposure schedules on cell via-
bility, an ANOVA was conducted that used the periods of
culture as independent factors. Statistical significance was
assessed by Tukey HSD and Bonferroni post hoc tests. A
one-way ANOVA with Tukey HSD post hoc was conducted
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Figure 1: Doxorubicin-induced cytotoxicity. MCF-7 and KGN cells were exposed to Dox 0, 5, 10, 25𝜇M for (a) 24h (24H+), (b) 24h exposure
and 24h culture with medium (24H+24H-), (c) 24h exposure and 48h culture with medium (24H+48H-), or (d) 72h continuous exposure
(72H+). Complete RPMI (MCF-7) or DMEM/F12 (KGN) without Dox (0𝜇M) was used as a control. Cell viability was assessed by a crystal
violet assay, in which cell numberwas obtained by comparison with a standard curve and% cell viability was calculated frommedium control.
Means ± SD of 3 independent experiments shown. Data analysed by one-way ANOVAwith Tukey’s post hoc test.∗p ≤ 0.05; ∗∗ p ≤ 0.01, ∗∗∗
p ≤ 0.0001 compared to control.
to examine estrogen production. These statistical analyses
were performed using SPSS statistics software (V22.0 IBM,
Australia). Statistical significance was set at p ≤ 0.05. All
experiments were performed as three independent replicates,
and all data expressed as mean ± standard deviation.
4. Results
KGN (25,000) and MCF-7 (20,000) cells were added to each
well, and after 24h adherence and 24h culture in control
conditions, there were 113,600±15,600 KGN cells/well and
38,100±4400 MCF-7 cells/well. After 24h adherence and 72h
in culture there were 119072±8750 KGN and 83383±13546
MCF-7 cells per well in control medium.
Doxorubicin killed bothMCF-7 andKGNcells (Figure 1).
A 24h exposure to 5𝜇M Dox significantly decreased MCF-7
to 46±22% (p<0.0001) and KGN to 65±3% (p<0.01) percent
of control (n=3, Figure 1(a)). Cells were exposed to Dox
for 24h, then the cells were washed and cultured for an
additional 24 or 48h in medium alone (Figures 1(b) and 1(c))
with media replenished at 24h intervals. There was a time-
dependent decrease in the numbers of viable cells during
the subsequent 48h culture (Figures 1(b) and 1(c)). There
were similar numbers of viable cells after 72h continuous
exposure to Dox (with media replenishment every 24h,
Figure 1(d)) as those after 24h exposure and a further 48h
culture (Figure 1(c)).
4-Cyc had no effect on KGN cell viability (Figure 2(a))
and only the longest 72h exposure to the highest concentra-
tion (2.5𝜇M) of 4-Cyc significantly reduced the numbers of
viable MCF-7 cells to 56354±1657 cells per well (p<0.05).
Exposure to 𝛼Toc had no significant effect on MCF-7
or KGN cell viability (Figure 3) but 𝛾-Toc was significantly
more cytotoxic to MCF-7 cells than to KGN cells (Figure 4).
A dose- and time-dependent decrease in MCF-7 cell viability
were observed after a 24h or a 72h continuous exposure to
𝛾Toc (Figure 4), but increasing concentrations of 𝛾Toc had
no significant effects on KGN cell viability compared to the
vehicle control (Figure 4).The percentage of viable KGN cells
after 24h exposure to 100𝜇M 𝛾Toc was 113±16% per cells/well,
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Figure 2: Effect of 4-Cyc on cell viability. (a) MCF-7 and (b) KGN cells were exposed to 4-Cyc 0, 0.5, 1, 2.5𝜇M for 24h exposure (24H+),
24h exposure and 24h culture with media (24H+24H-), 24h exposure and 48h culture with media (24H+48H-), or 72h continuous exposure
(72H+). Complete RPMI or DMEM/F12 without 4-Cyc (0𝜇M) was used as a control. Cell viability was assessed by a crystal violet assay, in
which cell number was obtained by comparison with a standard curve and % cell viability was calculated frommedium control. Means ± SD
of 3 independent experiments shown. Data analysed by one-way ANOVAwith Tukey’s post hoc test.
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Figure 3: Effect of 𝛼Toc on cell viability. MCF-7 andKGN cells were exposed to 𝛼Toc 0, 50, 75, 100𝜇M for 24h exposure (24H+), 24h exposure
and 24h culturewithmedia (24H+24H-), 24h exposure and 48h culturewithmedia (24H+48H-), or 72h continuous exposure (72H+). Culture
media containing 0.8% DMSO was used as a control. Cell viability was assessed by a crystal violet assay, in which cell number was obtained
by comparison with a standard curve and % cell viability was calculated from vehicle control. Means ± SD of 3 independent experiments
shown. Data analysed by one-way ANOVA with Tukey’s post hoc test.
similar to the percentage of viable cells after exposure to the
same concentration of 𝛼Toc (109±13% cells/well, Figure 3).
The viability ofMCF-7 cellswas reduced to 31±7%percent
of control by a 24h exposure to the low concentration
combination of Dox (10𝜇M) and 4-Cyc (1𝜇M), similar to that
observed with the same (10𝜇M) concentration of Dox alone
(data not shown). When the MCF-7 cells were exposed to
the combination of higher concentrations of Dox (25𝜇M)
and 4-Cyc (2.5𝜇M) for 24h, the combination also had the
same effect as Dox (25𝜇M) alone; viable MCF-7 cells were
reduced to 16±6% of control (Figure 5(a)). Adding 𝛼Toc to
this combination had no effect on cell viability (23±7% of
control), but the addition of 𝛾Toc (75𝜇M) to the combination
decreased MCF-7 cell viability to 9±3% cells per well after
24h exposure, significantly lower than Dox alone (p<0.05,
Figure 5(a)) or 4-Cyc alone (2.5𝜇M, Figure 2(a), 95±13% of
control), or compared to the combination of Dox and 4-Cyc
(Figure 5(a)).
The combination of Dox (25𝜇M) and 4-Cyc (2.5𝜇M)
caused significantly more KGN cell death than Dox alone
(Figure 5(b)). After 72h exposure to this combination there
were 1763±1494 KGN cells per well (1.4±1 % of control,
Figure 5(b)), significantly lower than those after a 72h expo-
sure to Dox alone (10555±4797, p<0.01), equivalent to 8.7±3.4
percent of control (Figure 5(b)). The addition of 𝛼Toc to this
combination reducedKGNcell death so that it was the similar
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Figure 4: Effect of 𝛾Toc on cell viability. MCF-7 andKGN cells were exposed to 𝛾Toc 0, 50, 75, 100𝜇M for 24h exposure (24H+), 24h exposure
and 24h culture with media (24H+24H-), 24h exposure and 48h culture with media (24H+48H-), or 72h continuous exposure (72H+). 0.8%
DMSO in RPMI or DMEM/F12 was used as a control. Cell viability was assessed by a crystal violet assay, in which cell number was obtained
by comparison with a standard curve and % cell viability was calculated from vehicle control. Means ± SD of 3 independent experiments
shown. Data analysed by one-way ANOVA with Tukey’s post hoc test. ∗p ≤ 0.05; ∗∗ p ≤ 0.01, ∗ ∗ ∗ p ≤ 0.0001 compared to control.
to Dox alone, 7305±1823 cells per well, equivalent to 7.9±1
percent of control (Figure 5(b)). The addition of 𝛾Toc to the
combination did not augment the cytotoxicity of Dox and
4-Cyc in KGN cells (Figure 5(a)). Overall, 𝛾Toc combined
with Dox and 4-Cyc wasmore cytotoxic towardsMCF-7 than
KGN cells in the first 24h of culture (Figure 5).
After 24h culture KGN cells produced 1.2±0.1 pg/cell
of estrogen and 0.8±0.08 pg/cell in the last 24h of a 72h
culture under control conditions (Figures 6(a) and 6(b)).
A 24h exposure to 5𝜇M Dox significantly reduced KGN
cell viability (Figure 1(a)) but had no effect on estrogen per
cell production, which was 1.2±0.03 pg/cell (Figure 6(a)).
However, a continuous 72h exposure to Dox, during which
media were replenished every 24h and the number of viable
cells decreased (Figure 1(d)), caused a significant increase
to 13±3 pg/cell (p<0.01, Figure 6(a)) in the last 24h culture
period. The same 72h continuous exposure to 2.5𝜇M 4-Cyc
had no effect on cell viability (Figure 2(b)) and no effect on
estrogen production, which was 0.81±0.08 pg/cell in the last
24h culture period (Figure 6(b)).
When KGN cells were exposed to tocopherols, the
24h+48h- control KGN cells were exposed to almost the same
conditions as the 72h+ control cells, 72h in vitro with media
replenished every 24h. The only difference was that the 72h+
continuously exposed cells were cultured with 0.8% DMSO
throughout, whereas the 24h+48h- control KGN cells were
only cultured in the presence of 0.8%DMSO for the first 24h.
The 72h+ exposure to 0.8%DMSOdid not significantly affect
KGNcell viability (Figure 3(b)), but it stimulated significantly
more estrogen production (1.32±0.07 pg/cell) in the last
24h period of culture than the 24h+48h- exposure which
supported production of 0.76±0.14 pg/cell (p< 0.05, Figures
6(c) and 6(d)).
KGN cells in the 0.8% DMSO control produced 1.1±0.4
pg/cell after 24h in vitro. The same 24h exposure to 𝛼Toc
had no effect on estrogen per cell production (Figure 6(c))
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Figure 5: Cytotoxicity of combined chemotherapeutic regime. (a) MCF-7 and (b) KGN cells were exposed to a combination of chemothera-
peutics (25𝜇MDox + 2.5𝜇M 4-Cyc), or a combination of chemotherapeutics + 75𝜇M 𝛼Toc, or a combination of chemotherapeutics + 75𝜇M
𝛾Toc for 24h (24H+); 24h exposure and 24h culture with media (24H+24H-); 24h exposure and 48h culture with media (24H+48H-); or 72h
continuous exposure (72H+). Cell viability was assessed by a crystal violet assay, in which cell number was obtained by comparison with a
standard cue and % cell viability was calculated from vehicle control. Means ± SD of 3 independent experiments shown. Data analysed by
one-way ANOVAwith Tukey’s post hoc test. ∗p ≤ 0.05; ∗∗ p ≤ 0.01, ∗∗∗ p ≤ 0.0001 compared to control same concentration of doxorubicin
alone (25𝜇M).
whereas 100𝜇M 𝛾Toc stimulated the production of 1.6±0.5
pg/cell (Figure 6(d)). A 72h continuous exposure to either
𝛼Toc or 𝛾Toc significantly reduced estrogen per cell produc-
tion compared to control medium containing 0.8% DMSO
(Figures 6(c) and 6(d)). The highest (100𝜇M) concentration
of 𝛼Toc and 𝛾Toc supported higher levels of estrogen synthe-
sis than the lowest (50𝜇M) concentrations of the tocopherols.
A continuous 72h exposure to the combination of Dox
and 4-Cyc reduced cell viability (Figure 5(b)) but stimulated
the highest recorded estrogen per cell production; 39±22
pg/cell in the last 24h culture period (Figure 7).This was also
higher than the estrogen per cell concentration caused by 72h
exposure to Dox alone (Figure 6(a)). The addition of 𝛼Toc or
𝛾Toc to the combination ofDox and 4-Cyc had no statistically
significant effect on estrogen per cell production (Figure 7),
although it was noted that 72h exposure to the combination
of Dox and 4-Cyc with 75𝜇M 𝛼Toc resulted in 13±2 pg/
cell.
5. Discussion
The combination of Dox and cyclophosphamide has been
used as a standard chemotherapy option for breast cancer
patients since 1975 [3, 66]. Although it is a successful
treatment for breast cancer [2], it causes premature ovarian
failure and infertility [10].This study showed for the first time
that the combination of Dox and 4-Cyc caused the same cyto-
toxicity to MCF-7 breast cancer cells in vitro as Dox alone,
but there were different cytotoxic effects towards the KGN
ovarian granulosa cell line; the Dox and 4-Cyc combination
was significantly more cytotoxic than Dox alone. Similarly,
𝛾Toc affected the two cell lines differently; it augmented
the cytotoxicity of the Dox and 4-Cyc combination towards
MCF-7 cells but did not affect cytotoxicity of the combination
towards the KGN cells.
Breast cancer patients are administered multiple cycles of
Dox and cyclophosphamide [3], and although this can result
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Figure 6: Effect of chemotherapeuticsand tocopherols on estrogen production. KGN cells were exposed toDox (0, 5, 10, 25𝜇M), 4-Cyc (0, 0.5,
1, 2.5𝜇M), 𝛼Toc (0, 50, 75, 100𝜇M) or 𝛾Toc (0, 50, 75, 100𝜇M) for 24h exposure (24h+), 24h exposure and 24h culture with fresh DMEM/F-12
complete medium (24h+24h-), 24h exposure and 48h culture with DMEM/F-12 complete medium (24h+48h-), or 72h continuous exposure
where reagents in medium + 10% FCSwere replenished every 24h (72h+). Estrogen production was assessed in supernatant at the end of each
exposure using an estradiol Enzyme-Linked Immunoassay, in which concentration of estrogen (pg/mL) was obtained by comparison with a
standard curve, and estrogen/cell concentration was calculated by dividing pg/mL of estrogen by the number of viable cells in the same well.
Means ± SD of 3 independent experiments shown. Data analysed by one-way ANOVAwith Tukey’s post hoc test.∗p ≤ 0.05; ∗∗ p ≤ 0.01, ∗∗∗
p ≤ 0.0001 compared to the same exposure control.
in 90% survival for 5y [2], chemotherapeutic-resistant cells
are known to cause recurrence of the cancer. The exposure
and culture schedules used in this in vitro study resulted
in only 54% of MCF-7 and 35% of KGN cells being killed
in the first 24h of exposure. In our in vitro model ‘viable’
meant cells were adherent to the floor of the culture vessel,
whereas nonadherent dead cells werewashed away. Cells with
damaged DNA may still function and adhere to the culture
vessel, and it is likely that DNA damage is only manifested
as cell death or loss in the crystal violet assay when the cell
attempts to go through mitosis. Since the doubling time for
MCF-7 is 29h [67] and was originally reported as being 46h
for the KGN cell line [64], we expected to see further cell loss
in the 48–72h following removal of the chemotherapeutics,
and this proved to be the case; fewer than 10% of the cells
were viable after 72h in vitro. We conclude that additional
time in culture, sufficient for the MCF-7 to undergo mitosis,
would be needed to be able to determine if this surviving
≤10% would give rise to Dox-resistant cells or if these would
also die. Further development is required to determine if
this in vitro system can be used to derive chemoresistant
cells.
Resistance or sensitivity to chemotherapeutics in vivo is
affected by a number of interacting factors including the
hepatic clearance of the chemotherapeutics and intracellu-
lar levels of metabolising enzymes such as glutathione S-
transferase [68] or aldehyde dehydrogenase, which in vitro
metabolises 4-Cyc to its inactive form [18]. KGN cells were
more sensitive to Dox but less sensitive to 4-Cyc than MCF-7
cells. We concluded this because a 72h continuous exposure
to 4-Cyc reduced the number of viable MCF-7 cells but had
no effect on KGN cells. It is possible that KGN cells express
higher levels of aldehyde dehydrogenase than MCF-7 cells
and hence metabolised 4-Cyc to its inactive form [62].
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Figure 7: Effect of chemotherapeutics and tocopherols on estrogen
production. Combined chemotherapeutic regime (25𝜇M Dox with
2.5𝜇M4-Cyc), combined regime + 75𝜇M 𝛼Toc, or combined regime
+ 75𝜇M 𝛾Toc for 24h exposure (24h+), 24h exposure and 24h
culture with fresh DMEM/F-12 complete medium (24h+24h-), 24h
exposure and 48h culture with DMEM/F-12 complete medium
(24h+48h-), or 72h continuous exposure where reagents in medium
+ 10% FCSwere replenished every 24h (72h+). Estrogen production
was assessed in supernatant at the end of each exposure by using an
estradiol ELISA, in which concentration of estrogen (pg/mL) was
obtained by comparison with a standard curve, and estrogen/cell
concentration was calculated by dividing pg/mL of estrogen by
the number of viable cells in the same well. Means ± SD of
3 independent experiments shown. Data analysed by one-way
ANOVA with Tukey’s post hoc test. ∗p ≤ 0.05; ∗∗ p ≤ 0.01, ∗ ∗ ∗
p ≤ 0.0001 compared to control same concentration of doxorubicin
alone (10𝜇M).
A relatively short 24h in vitro exposure to 2.5𝜇M 4-
Cyc had no effect on MCF-7 cells, although this con-
centration is two orders of magnitude higher than the
plasma concentration (0.02𝜇M) of the pharmacologically
equivalent 4-hydroxycyclophosphamide 2-24h after admin-
istration of cyclophosphamide in vivo. The pharmacokinet-
ics of cyclophosphamide has been well characterised [69–
71], but much less is known about the kinetics of the
metabolites of cyclophosphamide. The hepatic metabolite 4-
hydroxycyclophosphamide has a plasma half-life of only a
few minutes in vivo [71] because it undergoes spontaneous
alteration into phosphoramide mustard [17, 18]. However,
phosphoramide mustard may be ionised at physiological pH
with a consequent reduction in cytotoxicity, and the oxi-
dation of 4-hydroxycyclophosphamide can produce inactive
metabolites [71]. Therefore, the clinically relevant dose of
cyclophosphamide necessary to treat breast cancer patients
might differ from the in vitro effective concentration.
Dox was more cytotoxic to MCF-7 cells than 4-Cyc.
Although 2.5𝜇M 4-Cyc did kill MCF-7 cells after 72h con-
tinuous exposure, when the same 2.5𝜇M concentration of
4-Cyc was combined with Dox for 72h, the numbers of
surviving cells were comparable to those recorded after
exposure to Dox alone, suggesting that in this in vitro model
4-Cyc did not potentiate the in vitro effect of Dox in the
MCF-7 cells. Corbett et al. [26] found that the growth of
murine mammary adenocarcinomas in vivo was slower after
administration of Dox as a single agent than after cyclophos-
phamide alone, meaning that the Dox was more cytotoxic
than cyclophosphamide in vivo. However, the combination of
Dox and cyclophosphamide delayed the in vivo development
of mammary adenocarcinomas for longer than after the
administration of each single agent [26] which suggested
therapeutic synergism between the two chemotherapeutics in
vivo.
The combination of Dox and 4-Cyc reduced MCF-7 via-
bility by 85% whereas exposure to 75𝜇M 𝛾Toc for 24h caused
a 20% reduction in viable cell numbers.The addition of 75𝜇M
𝛾Toc to Dox and 4-Cyc for 24h reduced cell viability by 91%,
less than the amount of cytotoxicity predicted by adding the
activity of 𝛾Toc to Dox and 4-Cyc. More studies using lower
concentrations of reagents are needed to determine if there
are synergistic interactions between 𝛾Toc, Dox, and 4-Cyc.
A long 72h continuous exposure to 2.5𝜇M 4-Cyc had no
effect on KGN cell viability nor estrogen per cell production,
a 72h exposure to Dox was cytotoxic, and exposure to the
combination of Dox and 2.5𝜇M 4-Cyc was more cytotoxic
than exposure to Dox alone. This result suggested synergism
between Dox and 4-Cyc, but a mechanism for that synergism
cannot be deduced from this study. It is possible that 4-Cyc
caused DNA crosslinking [18], but this damage was repaired
in KGN cells exposed to 4-Cyc alone, whereas the addition of
Dox to 4-Cyc prevented the damage from being repaired [27]
and hence caused KGN cell death.
In a previous study, KGN cells incubated with
androstenedione for 72h synthesised and secreted significant
amounts of estrogen into the culture medium [64]. In
the present study, a 24h culture in DMEM/F-12 medium
containing 10% FCS and ITS resulted in the production of
1.2±0.1 pg/cell, and that rate of production was maintained
for 72h when the culture medium was replenished every
24h. Foetal calf serum is rich in fatty acids and cholesterol,
the substrate for the whole steroidogenic pathway [72]. Fatty
acids, like arachidonic acid, play an essential role in StAR
protein expression [73] and the in vitro synthesis of steroid
hormones such as progesterone and estrogen. In this study,
the use of DMEM/F12 with 10% FCS and ITS was enough to
support steroidogenesis; androstenedione was not required
to support estrogen synthesis and secretion.
Bak et al. [53] reported that estrogen induced the expres-
sion of cyclin D1 and c-myc and hence increased mitosis in
MCF-7 cells in vitro, and that 𝛾Toc, but not 𝛼Toc, inhibited
expression of these cell-cycle genes and reduced estrogen-
stimulated MCF-7 cell proliferation. The MCF-7 cells in our
study were not exposed to estrogen; therefore this was not the
cause of the significant cell death caused by 𝛾Toc in our study,
suggesting that 𝛾Toc is cytotoxic through another estrogen-
independent mechanism of action. Lee et al. [61] showed that
𝛾Toc was cytotoxic to breast cancer cells because it enhanced
the transactivation of PPAR𝛾 which caused apoptosis and
inhibited cell-cycle progression. 𝛾Toc has also shown anti-
cancer activity in numerous cancer models, including colon
[74], prostate [75], and lung cancer [76] in the absence of
estrogen. KGN cells synthesised estrogen, which raises the
possibility that there may have been interactions between
estrogen and 𝛾Toc, but 𝛾Toc alone did not cause cytotoxicity
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towards KGN cells in the presence of 75 to 183 pg/mL
estrogen, and neither did 𝛾Toc increase the cytotoxicity of
the combination of Dox and 4-Cyc, which suggests that the
proapoptotic effect that Bak et al. [53] reported in estrogen-
stimulated MCF-7 exposed to 𝛾Toc does not apply to KGN
cells.
Exposure to Dox for 72h caused significant KGN cell
death and, counterintuitively, also caused a significant
increase in estrogen production per KGN cell. This effect
has been reported in other steroid hormone-synthesising
reproductive cell lines in vitro. An extract from amarine snail
was significantly cytotoxic to a human Jar choriocarcinoma
placental cell line. As the number of viable cells decreased,
secreted progesterone increased [77]. Gross et al. [78] also
described dying primary-derived granulosa cells increasing
progesterone production. It is possible that the cytotoxic
mechanisms of action in these cases disrupted membranes
and dysregulated steroidogenesis, resulting in massive over-
production of steroid hormones. This confounding effect
might be avoided in future by measuring production of
another nonsteroid hormone, AMH, which is important for
fertility.
Four test reagents (𝛾Toc, 𝛼Toc, Dox, and 4-Cyc) were
each tested at several different concentrations in four expo-
sure schedules. This generated a relatively high number of
test conditions which justified the use of human cell lines.
Further studies examining ROS generation and cell death
will support the selection of a reduced number of test
conditions. At this point MCF-7 cells could be replaced with
heterogeneous populations of primary-derived breast cancer
cells from different tumour types, and the KGNS could be
replaced with 3D primary-derived ovarian follicle culture
[79] to better model the effects of chemotherapeutics with or
without tocopherols on breast cancer and the ovary.
In summary, 4-Cyc was active because a 72h continuous
exposure killed MCF-7 cells and reduced KGN estrogen
per cell production. Both 𝛾Toc and Dox (applied as single
agents) significantly reduced the numbers of viable MCF-7
and KGN cells within 24h of exposure, whilst 𝛼Toc reduced
the cytotoxic effects of the Dox and 4-Cyc combination in
KGN cells. The 4-Cyc concentration, despite two orders of
magnitude higher than effective clinical plasma concentra-
tions, may have been too low for this in vitro model; hence
we do not exclude the possibility of therapeutic synergism
of the Dox and 4-Cyc combination in MCF-7 cells too. Our
hypotheses were partially supported: although the Dox and
4-Cyc combination was not more cytotoxic than Dox alone
towards MCF-7 cells, the combination displayed therapeutic
synergism towards the ovarian KGN granulosa cells. 𝛾Toc,
but not 𝛼Toc, augmented the cytotoxic activity of Dox and
4-Cyc in the MCF-7 cells, but not the KGN cells. This study
supports further work to explore the potential of 𝛾Toc to
increase the chemotherapeutic efficacy of Dox and 4-Cyc
against breast cancer cells in vitro.
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